Cargando…

A174 A NOVEL MECHANISM OF CROHN’S DISEASE SEVERITY IN WOMEN: EVALUATING THE IMPACT OF AN ESTROGEN-FARNESOID X RECEPTOR INTERACTION ON INTESTINAL BARRIER FUNCTION

BACKGROUND: Crohn’s disease (CD) is associated with deficits in intestinal barrier function. Activation of bile acid-sensing nuclear receptor Farnesoid X receptor (NR1H4, FXR) is associated with protective effects against reduced intestinal barrier function; namely through promoting tight junction c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, D, Donovan, L, Choi, J, Kim, R, Schwarz, U, Wilson, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991304/ http://dx.doi.org/10.1093/jcag/gwac036.174

Ejemplares similares

Genetic variation in the farnesoid X-receptor predicts Crohn’s disease severity in female patients
por: Wilson, Aze, et al.
Publicado: (2020)

Association of IL-6 promoter polymorphism -174C/G with outcome in severe sepsis
por: Sabelnikovs, O, et al.
Publicado: (2008)

A65 VISCERAL FAT INDICES: DO THEY HELP DIFFERENTIATE CROHN’S DISEASE AND INTESTINAL TUBERCULOSIS IN CHILDREN?
por: Srivastava, A, et al.
Publicado: (2023)

Effect of the IL-6 promoter polymorphism -174 G/C on risk and outcome of pneumonia
por: Martín-Loeches, I, et al.
Publicado: (2008)

A192 EFFICACY OF USTEKINUMAB IN SMALL BOWEL STRICTURES OF FIBROSTENOTIC CROHN'S DISEASE AS ASSESSED BY INTESTINAL ULTRASOUND
por: St-Pierre, J, et al.
Publicado: (2023)

Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice
por: Ikpa, Pauline T., et al.
Publicado: (2019)

The relationship of adiposity to disease severity in a Crohn's patient cohort
por: O’Connor, DJ, et al.
Publicado: (2015)

Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
por: Tang, Kaijia, et al.
Publicado: (2022)

Pharmacological Activation of the Bile Acid Nuclear Farnesoid X Receptor Is Feasible in Patients with Quiescent Crohn's Colitis
por: van Schaik, Fiona D. M., et al.
Publicado: (2012)

P02.174. Effectiveness of acupuncture in improving perioperative patient centered outcomes: a comparative effectiveness study
por: Attias, S, et al.
Publicado: (2012)

Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats
por: Ceulemans, Laurens J., et al.
Publicado: (2017)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

P174: A model for infection control collaboration among municipalities and 3 university hospitals in the capital region, Denmark
por: Thye, A-M, et al.
Publicado: (2013)

T174. ANTIPSYCHOTICS AND THE MICROBIOME
por: Chen, Anderson, et al.
Publicado: (2020)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

AB174. VHL protein: a new therapeutic target of renal cell carcinoma
por: Wang, Jiangyi, et al.
Publicado: (2015)

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
por: Jiang, Changtao, et al.
Publicado: (2015)

Enhanced Alcoholic Liver Disease in Mice with Intestine-specific Farnesoid X Receptor Deficiency
por: Huang, Mingxing, et al.
Publicado: (2020)

Estrogen decreases inflammation and apoptotic signaling in the heart following severe burn injury
por: Gatson, JW, et al.
Publicado: (2010)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity
por: Anderson, Kemp M., et al.
Publicado: (2021)

Intestinal Farnesoid X Receptor Activation by Pharmacologic Inhibition of the Organic Solute Transporter α-β
por: van de Wiel, Sandra M.W., et al.
Publicado: (2017)

Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor
por: Gadaleta, Raffaella Maria, et al.
Publicado: (2020)

A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis
por: Zhao, Long, et al.
Publicado: (2020)

Hall 174
por: Jacob, U
Publicado: (1977)

Early administration of parenteral estrogen suppresses the deleterious local and systemic inflammatory response in severe burns
por: Wigginton, JG, et al.
Publicado: (2012)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Granuloma-in-follicles in pediatric Crohn’s disease
por: Janssen, Carl EI, et al.
Publicado: (2011)

Influence of varying estrogen levels on trigeminal CGRP release in healthy women
por: Ibrahimi, K, et al.
Publicado: (2013)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

A205 EVALUATING THE ASSOCIATION BETWEEN PERIPHERAL BLOOD EOSINOPHILS AND DRUG RESPONSE IN CROHN'S DISEASE: CONTINUING ANALYSIS
por: Cai, B, et al.
Publicado: (2023)

Fecal S100A12 levels measured by a new ELISA are increased in ulcerative colitis (UC) and Crohn’s disease (CD) and correlates with intestinal damage
por: Garnero, P, et al.
Publicado: (2010)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor
por: Tveter, Kevin M, et al.
Publicado: (2020)

Intestinal Farnesoid X Receptor Modulates Duodenal Surface Area but Does Not Control Glucose Absorption in Mice
por: Yang, Jiufang, et al.
Publicado: (2023)

Early administration of a single dose of parenteral estrogen decreases inflammation in the heart for 45 days after severe burns
por: Pepe, PE, et al.
Publicado: (2013)

Immunological modulation of estrogen during sepsis
por: Stabile, AM, et al.
Publicado: (2012)

Clinical response to the canakinumab in crohn’s disease related artrhritis
por: Gündüz, Zübeyde, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6bs7sfuuht5lqv2kbf8unrvbcv